Apellis Says Mixed Phase III Results Position Geographic Atrophy Candidate For Filing
Apellis plans to file pegcetacoplan for approval as the first drug to treat the advanced AMD condition geographic atrophy, despite the C3 inhibitor hitting its endpoint in only one of two pivotal trials.
You may also be interested in...
One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.
The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.
An $8bn public-to-private takeout by two private equity firms of the Swedish rare disease specialist collapses because total tenders to the offer fell below a 90% threshold.